Escherich Carolin S, Chen Wenan, Li Yizhen, Yang Wenjian, Nishii Rina, Li Zhenhua, Raetz Elizabeth A, Devidas Meenakshi, Wu Gang, Nichols Kim E, Inaba Hiroto, Pui Ching-Hon, Jeha Sima, Camitta Bruce M, Larsen Eric, Hunger Stephen P, Loh Mignon L, Yang Jun J
Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
Department for Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich-Heine University, Duesseldorf, Germany.
Blood. 2024 May 30;143(22):2270-2283. doi: 10.1182/blood.2023023336.
Biallelic mutation in the DNA-damage repair gene NBN is the genetic cause of Nijmegen breakage syndrome, which is associated with predisposition to lymphoid malignancies. Heterozygous carriers of germ line NBN variants may also be at risk for leukemia development, although this is much less characterized. By sequencing 4325 pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL), we systematically examined the frequency of germ line NBN variants and identified 25 unique, putatively damaging NBN coding variants in 50 patients. Compared with the frequency of NBN variants in gnomAD noncancer controls (189 unique, putatively damaging NBN coding variants in 472 of 118 479 individuals), we found significant overrepresentation in pediatric B-ALL (P = .004; odds ratio, 1.8). Most B-ALL-risk variants were missense and cluster within the NBN N-terminal domains. Using 2 functional assays, we verified 14 of 25 variants with severe loss-of-function phenotypes and thus classified these as nonfunctional or partially functional. Finally, we found that germ line NBN variant carriers, all of whom were identified as heterozygous genotypes, showed similar survival outcomes relative to those with wild type status. Taken together, our findings provide novel insights into the genetic predisposition to B-ALL, and the impact of NBN variants on protein function and suggest that heterozygous NBN variant carriers may safely receive B-ALL therapy. These trials were registered at www.clinicaltrials.gov as #NCT01225874, NCT00075725, NCT00103285, NCI-T93-0101D, and NCT00137111.
DNA损伤修复基因NBN的双等位基因突变是尼美根断裂综合征的遗传病因,该综合征与淋巴系统恶性肿瘤的易感性相关。生殖系NBN变异的杂合携带者也可能有患白血病的风险,尽管对此的描述要少得多。通过对4325例B细胞急性淋巴细胞白血病(B-ALL)儿科患者进行测序,我们系统地检测了生殖系NBN变异的频率,并在50例患者中鉴定出25种独特的、可能具有损害性的NBN编码变异。与gnomAD非癌症对照中NBN变异的频率(118479人中的472人中有189种独特的、可能具有损害性的NBN编码变异)相比,我们发现儿科B-ALL中NBN变异显著过量(P = 0.004;优势比,1.8)。大多数B-ALL风险变异为错义变异,且聚集在NBN N端结构域内。使用两种功能分析方法,我们验证了25种变异中的14种具有严重功能丧失表型,因此将这些变异分类为无功能或部分功能变异。最后,我们发现生殖系NBN变异携带者(均被鉴定为杂合基因型)与野生型携带者相比,生存结果相似。综上所述,我们的研究结果为B-ALL的遗传易感性、NBN变异对蛋白质功能的影响提供了新的见解,并表明杂合NBN变异携带者可能可以安全地接受B-ALL治疗。这些试验已在www.clinicaltrials.gov上注册,注册号为#NCT01225874、NCT00075725、NCT00103285、NCI-T93-0101D和NCT00137111。